Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 16/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561126 | 1.00 | TYMP (0.52) | TYMPKDM4ENPC1LMNAPDE3B | |
| SCHEMBL11160418 | 0.75 | APOBEC3G (0.40) | TYMPKDM4E | |
| SCHEMBL1445690 | 0.72 | TYMP (0.56) | TYMPNPC1LMNAPDE3BPDE3A | |
| SCHEMBL4560425 | 0.72 | TYMP (0.56) | TYMPNPC1LMNAPDE3BPDE3A | |
| SCHEMBL28448729 | 0.72 | TYMP (0.56) | TYMP | |
| SCHEMBL5163518 | 0.70 | TYMP (0.48) | TYMPNPC1LMNA | |
| Clopidol SCHEMBL11480048 | 0.69 | SLC2A1 (0.43) | KDM4EPDE3BPDE3A | |
| SCHEMBL9592776 | 0.69 | TYMP (0.46) | TYMPKDM4ENPC1LMNA | |
| SCHEMBL20799748 | 0.69 | TYMP (0.50) | TYMP | |
| SCHEMBL4560171 | 0.68 | TYMP (0.52) | TYMPKDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-01 | — | — | US | disclosed |
| EP-4472627-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118922185-A | N3-substituted uracil compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-106366073-A | Method for preparing tipiracil hydrochloride | 扬子江药业集团南京海陵药业有限公司 | 2017-02-01 | — | — | CN | disclosed |
| US-7666977-B2 | Poly(carbonate-co-urea) copolymers and melt transesterification method of preparing these copolymers | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| WO-2008136842-A1 | POLY( CARBONATE-CO-UREA) COPOLYMERS | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136841-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275206-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | GENERAL ELECTRIC COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275209-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | GENERAL ELECTRIC COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| EP-0151939-A2 | Pyrimidinediones and dihydroxypyrimidines, and process for the preparation of pyrimidinedones and dihydroxypyrimidines | BAYER AG (DE) | 1985-08-21 | — | — | EP | disclosed |
| US-4395406-A | 5-Halopyrimid-2-ones | NYEGAARD & CO. A/S (NO) | 1983-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, SLC28A1 | TYMP 276/4885KDM4E 4377/4885NPC1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.